Fate Therapeutics, Inc. (FATE)
1.28
-0.06
(-4.48%)
USD |
NASDAQ |
Nov 13, 16:00
1.275
0.00 (0.00%)
After-Hours: 19:59
Fate Therapeutics Price to Book Value : 1.169 for Nov. 13, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.169 |
| November 12, 2026 | 1.224 |
| November 11, 2026 | 1.466 |
| November 10, 2026 | 1.617 |
| November 09, 2026 | 1.772 |
| November 06, 2026 | 1.676 |
| November 05, 2026 | 1.690 |
| November 04, 2026 | 1.909 |
| November 03, 2026 | 1.864 |
| November 02, 2026 | 1.836 |
| October 30, 2026 | 1.900 |
| October 29, 2026 | 1.982 |
| October 28, 2026 | 1.982 |
| October 27, 2026 | 1.891 |
| October 26, 2026 | 1.877 |
| October 23, 2026 | 1.928 |
| October 22, 2026 | 1.909 |
| October 21, 2026 | 1.891 |
| October 20, 2026 | 1.882 |
| October 19, 2026 | 1.699 |
| October 16, 2026 | 1.635 |
| October 15, 2026 | 1.759 |
| October 14, 2026 | 1.772 |
| October 13, 2026 | 1.827 |
| October 12, 2026 | 1.946 |
| Date | Value |
|---|---|
| October 09, 2026 | 1.992 |
| October 08, 2026 | 1.946 |
| October 07, 2026 | 1.964 |
| October 06, 2026 | 2.092 |
| October 05, 2026 | 2.22 |
| October 02, 2026 | 2.120 |
| October 01, 2026 | 2.101 |
| September 30, 2026 | 2.165 |
| September 29, 2026 | 1.810 |
| September 28, 2026 | 1.810 |
| September 25, 2026 | 1.787 |
| September 24, 2026 | 1.772 |
| September 23, 2026 | 1.848 |
| September 22, 2026 | 1.962 |
| September 21, 2026 | 1.924 |
| September 18, 2026 | 1.924 |
| September 17, 2026 | 1.917 |
| September 16, 2026 | 1.856 |
| September 15, 2026 | 1.787 |
| September 14, 2026 | 1.780 |
| September 11, 2026 | 1.757 |
| September 10, 2026 | 1.772 |
| September 09, 2026 | 1.856 |
| September 08, 2026 | 1.901 |
| September 04, 2026 | 1.886 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AVITA Medical, Inc. | -- |
| Agenus, Inc. | -- |
| Amgen, Inc. | 17.55 |
| Anika Therapeutics, Inc. | 1.305 |
| BioCryst Pharmaceuticals, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 32.56 |
| Price | 1.28 |
| Earnings Yield | -80.48% |
| Market Cap | 155.56M |